Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma 05/23/2023 In a clinical trial of people with multiple myeloma, giving motixafortide with filgrastim markedly increased the number of stem cells that could be collected. The treatment may allow more people with this cancer to get optimal numbers of stem cells for a transplant. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892